Abbott Laboratories
Abbott’s Zika virus test given FDA authorisation
February 7, 2017Manufacturing and Production, Research and Development Abbott Laboratories, Zika virus
The threat of the Zika virus, though it may have disappeared from the headlines, is still very much present. Any …
Indian govt set to ban 1,200 fixed-dose combination drugs, reports
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abbott Laboratories, Pfizer, cough drug, pharma
Indian regulators are set to ban an additional 1,200 fixed-dose combinations, sent for probe by Drug Controller General of India …
UPDATE: Pfizer gets interim stay on cough syrup ban
March 15, 2016Manufacturing and Production, Research and Development Abbott Laboratories, Corex, Pfizer, Pfizer India
Shares in Pfizer India continued to tumble for a second day even as an Indian court granted the company a …
Abbott to table $25bn bid for medical device maker St Jude?
August 27, 2015Manufacturing and Production, Sales and Marketing Abbott Laboratories, mergers and acquisitions, st jude medical
Abbott Laboratories is said to be preparing a $25 billion takeover bid for medical device maker St Jude Medical. Illinois-based Abbott …
Abbott to split into two separate companies
October 20, 2011Manufacturing and Production, Research and Development, Sales and Marketing Abbott, Abbott Laboratories
Abbott’s management has decided to split the company into two separate entities in order to give shareholders a ‘distinct investment …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
Abbott hep C drug ABT-450/r impresses in mid-stage trial
November 2, 2010Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C
Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …
Latest content
Five Facts about cardiovascular disease
